RYR1 rs121918594: What Your Genotype Means
The genetic variant rs121918594 is a rare single-nucleotide change located in the RYR1 gene, which codes for the skeletal muscle calcium release channel. Inheriting an alternate allele at this position is associated with carrier status for malignant hyperthermia susceptibility type 1 and recessive RYR1-related central core disease. Because malignant hyperthermia can trigger a life-threatening hypermetabolic reaction to specific general anesthetics, identifying variants in this gene plays a crucial role in surgical safety planning.
What each genotype means
Typical RYR1 genotype
This is the most common genotype observed in the general population. It does not indicate the presence of the specific RYR1 variant associated with malignant hyperthermia susceptibility or central core disease.
This is the reference genotype and is found in the vast majority of the global population.
Potential carrier status
This genotype indicates you carry one copy of the variant associated with malignant hyperthermia susceptibility and recessive RYR1-related central core disease. Because this is a rare variant, you should discuss these findings with a medical professional or genetic counselor to understand your personal risk profile and clinical implications.
This genotype is very rare, with a global allele frequency of approximately 0.00001 in the gnomAD database.
Increased risk profile
This genotype indicates you carry two copies of the variant associated with malignant hyperthermia susceptibility and recessive RYR1-related central core disease. Individuals with this profile may have a higher risk for these conditions, and it is recommended to consult with a clinician regarding potential triggers for malignant hyperthermia.
This genotype is extremely rare in the general population.
Genetic Location and Molecular Identity
The single-nucleotide polymorphism rs121918594 represents a specific sequence change within the RYR1 gene, positioned on human chromosome 19. At this locus, the primary wild-type base is guanine (G), with the rare alternate allele being adenine (A). In genomic databases, this variation is classified as a missense change that alters the amino acid sequence of the resulting protein channel. The RYR1 gene is expansive, containing more than one hundred exons, and variations across its coding region are known to impact muscle excitation-contraction coupling. While common genetic polymorphisms frequently exert negligible biological effects, rare missense variants in RYR1 can alter channel kinetics. The rs121918594 variant is documented in public biomedical archives such as dbSNP, ClinVar, and PharmGKB, where it serves as a genetic marker evaluated for pharmacogenomic risks and inherited muscle disorders.
The Role of the RYR1 Gene in Muscle Function
The RYR1 gene provides the biological blueprint for ryanodine receptor 1, an essential intracellular calcium release channel predominantly situated in the sarcoplasmic reticulum membrane of skeletal muscle cells. During regular muscle contraction, electrical impulses traveling along motor neurons prompt the opening of these channels, rapidly releasing calcium ions into the intracellular fluid to activate the contractile machinery. Following contraction, calcium is actively pumped back into storage to enable muscle relaxation. When alterations occur within the structural domains of the ryanodine receptor, channel gating can become dysregulated, resulting in excessive or uncontrolled calcium leakage. This heightened intracellular calcium state can trigger sustained muscle rigidity, accelerate metabolic rates, and produce massive heat, forming the physiological basis for both chronic congenital myopathies and acute adverse drug reactions.
Clinical Associations and Strength of Evidence
Variants at rs121918594 are studied primarily in connection with two clinical scenarios: malignant hyperthermia susceptibility (MHS) and RYR1-related central core disease (CCD). Malignant hyperthermia is an autosomal dominant pharmacogenetic reaction triggered by exposure to volatile inhalational anesthetics—such as sevoflurane, desflurane, or halothane—and depolarizing neuromuscular blockers like succinylcholine. In clinical genomics catalogs, rs121918594 is designated as an indicator of carrier status, though the overall catalog evidence strength for this specific single-nucleotide polymorphism remains limited. Historically, while dozens of RYR1 variants have been functionally validated as definitively causative by groups like the European Malignant Hyperthermia Group, many rare alterations retain limited or uncertain classification due to low clinical case counts. In addition, when inherited alongside a second pathogenic mutation on the opposite chromosome, certain RYR1 variants contribute to recessive central core disease, characterized by muscle weakness and structural abnormalities on muscle biopsy.
Population Frequency and Ancestral Distribution
According to broad population sequencing initiatives, including the Genome Aggregation Database (gnomAD), the rs121918594 alternate allele is exceptionally uncommon. Its estimated global allele frequency is approximately 0.00001, meaning it is observed in only a minute fraction of the general population. Because it is an ultra-rare variant, comprehensive cross-ancestry comparative frequency statistics are constrained by sample sizes, and the variant may appear only sporadically across diverse ancestral cohorts. Unlike common benign single-nucleotide polymorphisms that are found in significant percentages of healthy individuals, rare pharmacogenetic and myopathy-associated RYR1 changes generally show low prevalence across European, African, Asian, and Admixed American populations. Consequently, the vast majority of people worldwide carry two copies of the common standard reference allele.
Navigating Genetic Results Safely
Direct-to-consumer raw genetic data or secondary genomic sequencing files must be interpreted with substantial clinical caution. Finding an alternate allele at rs121918594 indicates potential carrier status or susceptibility, but it does not represent an independent medical diagnosis. Individuals who discover an alternate allele should not alter their personal health routines without professional clinical guidance, but they should alert their surgical care teams, anesthesiologists, and pharmacists prior to undergoing any planned procedures requiring general anesthesia. In clinical practice, definitive evaluation of malignant hyperthermia susceptibility often combines formal clinical-grade diagnostic sequencing with specialized physiological tests, such as the caffeine-halothane contracture test (CHCT) or in vitro contracture test (IVCT). A medical geneticist or an anesthesia specialist can provide personalized risk stratification and family counseling.
How common is this variant?
The alternate allele at rs121918594 is extremely rare, with a gnomAD global allele frequency of approximately 0.00001. As a result, the overwhelming majority of individuals across all major continental ancestries carry the homozygous reference GG genotype.
Frequently asked questions
What is malignant hyperthermia?
Malignant hyperthermia is a severe pharmacogenetic condition that manifests during or after exposure to volatile inhalational general anesthetics or succinylcholine. It triggers uncontrolled calcium release in skeletal muscle, causing severe muscle rigidity, dangerously high body temperatures, and metabolic distress. When promptly recognized, it is managed with specialized medications like dantrolene and non-triggering alternative anesthetics.
Does carrying the rs121918594 variant mean I will definitely have a reaction to anesthesia?
No, carrying a susceptibility variant does not guarantee that a clinical reaction will occur. Genetic susceptibility exhibits variable expressivity and incomplete penetrance, meaning some carriers may undergo anesthesia without an event, while others experience severe complications. Because of this unpredictability, anesthesiologists take safe, proactive precautions whenever an RYR1 risk variant is identified.
Can rs121918594 cause muscle weakness outside of surgery?
Heterozygous carriers typically do not experience significant day-to-day muscle weakness, although some RYR1 variants are associated with mild heat intolerance or exercise-induced cramping. However, if a person inherits two disease-associated variants—one from each parent—they may develop recessive forms of RYR1-related congenital myopathy, such as central core disease, which involves chronic muscle weakness.
What should I tell my doctor if my genetic data shows this variant?
You should inform your physician, anesthesiologist, and surgical team that your genetic testing indicated an RYR1 variant associated with malignant hyperthermia susceptibility. They can verify the result with a certified clinical-grade genetic test and update your medical record to ensure non-triggering anesthetic protocols are utilized during any future surgical procedures.
Sources & further reading
Educational information only, last refreshed 9/7/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs121918594?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in RYR1
Pathogenic missense variant (p.Arg614Cys) associated with malignant hyperthermia susceptibility.
Well-characterized gain-of-function missense variant predisposing carriers to malignant hyperthermia crisis triggered by volatile inhaled anesthetics.
A variant in the RYR1 gene commonly referenced in clinical and consumer genomics databases.
This pathogenic variant is linked to Central core disease, a congenital myopathy.